Last update 03 Jan 2026

IBR-733

Overview

Basic Info

Drug Type
CAR-NK
Synonyms
Anti-CLL1/CD33 CAR T Cell(Guangzhou Bio-gene Technology), CLL1/CD33 CAR-T(Guangzhou Bio-gene Technology), ACC-NK733
+ [1]
Target
CD33 x CLL-1
Action
modulators
Mechanism
CD33 modulators(Myeloid cell surface antigen CD33 modulators), CLL-1 modulators(C-Type lectin domain family 12 member A modulators), Natural killer cell replacements
Therapeutic Areas
NeoplasmsHemic and Lymphatic Diseases
Active Indication
Refractory acute myeloid leukemiaRelapsing acute myeloid leukemia
Inactive Indication-
Originator Organization
Imbioray (Hangzhou) Biomedicine Co., Ltd.Imbioray (Hangzhou) Biomedicine Co., Ltd.
Active Organization
Imbioray (Hangzhou) Biomedicine Co., Ltd.Imbioray (Hangzhou) Biomedicine Co., Ltd.
Inactive Organization
Guangzhou Bio-gene Technology Co., Ltd.Guangzhou Bio-gene Technology Co., Ltd.
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with IBR-733
NCT06234904
/ Not yet recruitingPhase 1
An Open-label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR733 Cell Injection in Acute Myeloid Leukemia
NCT05943314
/ WithdrawnNot Applicable
Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in Refractory/Recurrent Acute Myeloid Leukemia: a Single-arm, Non-blind Clinical Study
100 Clinical Results associated with IBR-733
Login to view more data
100 Translational Medicine associated with IBR-733
Login to view more data
100 Patents (Medical) associated with IBR-733
Login to view more data
100 Deals associated with IBR-733
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 1
China
Imbioray (Hangzhou) Biomedicine Co., Ltd.Imbioray (Hangzhou) Biomedicine Co., Ltd.
01 Feb 2024
Relapsing acute myeloid leukemiaPhase 1
China
Imbioray (Hangzhou) Biomedicine Co., Ltd.Imbioray (Hangzhou) Biomedicine Co., Ltd.
01 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free